Lazard Capital Downgrades Abiomed (ABMD) to Hold
More News related to ABMD
- Lazard Capital Downgrades Abiomed (ABMD) to Hold
- Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
- Abiomed Announces Record Revenue of $20 Million for Second Quarter of Fiscal 2010
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Abiomed Second Fiscal Quarter 2010 Earnings and Conference Call Notification
More News related to Downgrades
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
- Unusual 11 Mid-Day Movers 11/24: IWA, DRAM, ABG, TIXC Higher; WH, WMG, ABIO, NYNY Lower
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
- Notable Mergers and Acquisitions of the Day 11/24: WIN/IWA, GMCR/DDRX, PLA
- Morning Movers 11/24: IWA, SEED, FEED, AEZS Higher; WH, ORS, ABIO, GRO, LONG Lower
Lazard Capital downgrades Abiomed (Nasdaq: ABMD) from Buy to Hold.
To see more analyst ratings on ABMD Click Here.
Abiomed Inc. is a provider of medical devices in circulatory support that offers a continuum of care in heart recovery to heart failure patients.
Related Categories
DowngradesStocks Mentioned
+0.20Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
